A review of epidermal growth factor receptor ligands in glucose homeostasis
-
By
-
Ka-Ying Chan
-
Chu-Jun Deng
-
Xi Chen
-
Yin Cai
-
Shiqi Jia
-
Chi-Ming Wong
-
May 29, 2026
-
Clinical Scorecard: An overview of the role of epidermal growth factor receptor ligands in regulating glucose balance
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Individuals with type 2 diabetes and those undergoing EGFR TKI treatment, with emphasis on the metabolic effects of TKIs. |
| Care Setting | |
Key Highlights
- First-generation EGFR inhibitors may improve glucose tolerance and insulin sensitivity by enhancing insulin signaling pathways.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor glucose levels regularly, especially in patients with a history of hyperglycemia; consider thresholds for intervention.
Risks
Patient & Prescribing Data
Chronic treatment for hyperglycemia may be necessary in patients on EGFR TKIs; consider metformin or other antihyperglycemic agents.
Clinical Best Practices
- Investigate the effects of EGFR ligands on beta cell mass in diabetic models; consider clinical trials to assess long-term outcomes.
Related Resources & Content
